Sequential changes in pancreatic markers in acute pancreatitis

Scandinavian Journal of Gastroenterology

Volumn 38, Issue 6, 2003, Pages 666-675

  Lempinen, M ^a   Stenman, U H ^a   Puolakkainen, P ^a   Hietaranta, A ^a   Haapiainen, R ^a   Kemppainen, Esko ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Acute pancreatitis; Pathophysiology; Trypsinogen

Indexed keywords

ALPHA 1 ANTITRYPSIN; APROTININ; TRYPSINOGEN; TRYPSINOGEN ACTIVATION PEPTIDE;

ACUTE PANCREATITIS; ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; DISEASE SEVERITY; EARLY DIAGNOSIS; ENZYME ASSAY; ENZYME BLOOD LEVEL; ENZYME IMMUNOASSAY; ENZYMURIA; FEMALE; FLUOROPHOTOMETRY; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; ALPHA 1-ANTITRYPSIN; BIOLOGICAL MARKERS; CARRIER PROTEINS; FEMALE; GROWTH SUBSTANCES; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PANCREATITIS; TIME FACTORS; TRYPSIN; TRYPSINOGEN;

EID: 0038649956     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365520310000357     Document Type: Article

References (46)

1. Steinberg W, Tenner S. Acute pancreatitis. N Engl J Med 1994;330:1198-210.
2. Beger HG, Bittner R, Block S, Buchler M. Bacterial contamination of pancreatic necrosis. A prospective clinical study. Gastroenterology 1986;91:433-8.
3. Reber HA. Acute pancreatitis: another piece of the puzzle? N Engl J Med 1991;325:423-5.
4. Steer ML. Classification and pathogenesis of pancreatitis. Surg Clin North Am 1989;69:467-80.
5. Steer ML. Frank Brooks memorial Lecture: the early intraacinar cell events which occur during acute pancreatitis. Pancreas 1998;17:31-7.
6. Hietaranta AJ, Saluja AK, Bhagat L, Singh VP, Song AM, Steer ML. Relationship between NF-kappaB and trypsinogen activation in rat pancreas after supramaximal caerulein stimulation. Biochem Biophys Res Commun 2001;280:388-95.
7. Whitcomb DC, Gorry MC, Preston RA, Furey W, Sossenheimer MJ, Ulrich CD, et al. Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. Nat Genet 1996;14:141-5.
8. Whitcomb DC. Early trypsinogen activation in acute pancreatitis. Gastroenterology 1999;116:770-2.
9. Marshall JB. Acute pancreatitis. A review with an emphasis on new developments. Arch Intern Med 1993;153:1185-98.
10. Itkonen O, Koivunen E, Hurme M, Alfthan H, Schröder T, Stenman UH. Time-resolved immunofluorometric assays for trypsinogen-1 and 2 in serum reveal preferential elevation of trypsinogen-2 in pancreatitis. J Lab Clin Med 1990;115:712-8.
11. Kassell B, Kay J. Zymogens of proteolytic enzymes. Science 1973;180:1022-7.
12. Sainio V, Puolakkainen P, Kemppainen E, Hedström J, Haapiainen R, Kivisaari L, et al. Serum trypsinogen-2 in the prediction of outcome in acute necrotizing pancreatitis. Scand J Gastroenterol 1996;31:818-24.
13. Gudgeon AM, Heath DI, Hurley P, Jehanli A, Patel G, Wilson C, et al. Trypsinogen activation peptides assay in the early prediction of severity of acute pancreatitis. Lancet 1990;335:4-8.
14. Tenner S, Fernandez-del Castillo C, Warshaw A, Steinberg W, Hermon-Taylor J, Valenzuela JE, et al. Urinary trypsinogen activation peptide (TAP) predicts severity in patients with acute pancreatitis. Int J Pancreatol 1997;21:105-10.
15. Neoptolemos JP, Kemppainen EA, Mayer JM, Fitzpatrick JM, Raraty MG, Slavin J, et al. Early prediction of severity in acute pancreatitis by urinary trypsinogen activation peptide: a multi-centre study [In Process Citation]. Lancet 2000;355:1955-60.
16. Pfützer RH, Barmada MM, Brunskill AP, Finch R, Hart PS, Neoptolemos J, et al. SPINK1/PSTI polymorphisms act as disease modifiers in familial and idiopathic chronic pancreatitis. Gastroenterology 2000;119:615-23.
17. Hedström J, Leinonen J, Sainio V, Stenman UH. Time-resolved immunofluorometric assay of trypsin-2 complexed with alpha 1-antitrypsin in serum. Clin Chem 1994;40:1761-5.
18. Borgström A, Ohlsson K. Immunoreactive trypsin in serum and peritoneal fluid in acute pancreatitis. Hoppe Seylers Z Physiol Chem 1978;359:677-81.
19. Bradley EL, 3rd. A clinically based classification system for acute pancreatitis. Summary of the international symposium on acute pancreatitis, Atlanta, GA, 11-13 September 1992. Arch Surg 1993;128:586-90.
20. Hedström J, Haglund C, Kemppainen E, Leinimaa M, Leinonen J, Stenman UH. Time-resolved immunofluorometric assay of trypsin-1 complexed with alpha(1)-antitrypsin in serum: increased immunoreactivity in patients with biliary tract cancer. Clin Chem 1999;45:1768-73.
21. Osman S, Turpeinen U, Itkonen O, Stenman UH. Optimization of a time-resolved immunofluorometric assay for tumor-associated trypsin inhibitor (TATI) using the streptavidin-biotin system. J Immunol Methods 1993;161:97-106.
22. Hurley PR, Cook A, Jehanli A, Austen BM, Hermon-Taylor J. Development of radioimmunoassays for free tetra-L-aspartyl-L-lysine trypsinogen activation peptides (TAP). J Immunol Methods 1988;111:195-203.
23. Appelros S, Thim L, Borgström A. Activation peptide of carboxypeptidase B in serum and urine in acute pancreatitis. Gut 1998;42:97-102.
24. Appelros S, Petersson U, Toh S, Johnson C, Borgström A. Activation peptide of carboxypeptidase B and anionic trypsinogen as early predictors of the severity of acute pancreatitis. Br J Surg 2001;88:216-21.
25. Müller CA, Appelros S, Uhl W, Büchler MW, Borgström A. Serum levels of procarboxypeptidase B and its activation peptide in patients with acute pancreatitis and non-pancreatic diseases. Gut 2002;51:229-35.
26. Kimland M, Russick C, Marks WH, Borgström A. Immunoreactive anionic and cationic trypsin in human serum. Clin Chim Acta 1989;184:31-46.
27. Borgström A, Ohlsson K. Studies on the turnover of endogenous cathodal trypsinogen in man. Eur J Clin Invest 1978;8:379-82.
28. Hedström J, Sainio V, Kemppainen E, Puolakkainen P, Haapiainen R, Kivilaakso E, et al. Urine trypsinogen-2 as marker of acute pancreatitis. Clin Chem 1996;42:685-90.
29. Petersson U, Appelros S, Borgström A. Different patterns in immunoreactive anionic and cationic trypsinogen in urine and serum in human acute pancreatitis. Int J Pancreatol 1999;25:165-70.
30. Hedström J, Korvuo A, Kenkimaki P, Tikanoja S, Haapiainen R, Kivilaakso E, et al. Urinary trypsinogen-2 test strip for acute pancreatitis. Lancet 1996;347:729-30.
31. Borgström A. The fate of intravenously injected trypsinogens in dogs. Scand J Gastroenterol 1981;16:281-7.
32. Borgström A, Lasson A. Trypsin-alpha 1-protease inhibitor complexes in serum and clinical course of acute pancreatitis. Scand J Gastroenterol 1984;19:1119-22.
33. Hedström J, Sainio V, Kemppainen E, Haapiainen R, Kivilaakso E, Schröder T, et al. Serum complex of trypsin 2 and alpha 1 antitrypsin as diagnostic and prognostic marker of acute pancreatitis: clinical study in consecutive patients. Br Med J 1996;313:333-7.
34. Hartwig W, Jimenez RE, Werner J, Lewandrowski KB, Warshaw AL, Fernandez-del Castillo C. Interstitial trypsinogen release and its relevance to the transformation of mild into necrotizing pancreatitis in rats. Gastroenterology 1999;117:717-25.
35. Pezzilli R, Billi P, Plate L, Barakat B, Bongiovanni F, Miglioli M. Human pancreatic secretory trypsin inhibitor in the assessment of the severity of acute pancreatitis. A comparison with C-reactive protein. J Clin Gastroenterol 1994;19:112-7.
36. Halila H, Huhtala ML, Schröder T, Kiviluoto T, Stenman UH. Pancreatic secretory trypsin inhibitor-like immunoreactivity in pancreatectomized patients. Clin Chim Acta 1985;153:209-16.
37. Iovanna J, Orelle B, Keim V, Dagorn JC. Messenger RNA sequence and expression of rat pancreatitis-associated protein, a lectin-related protein overexpressed during acute experimental pancreatitis. J Biol Chem 1991;266:24664-9.
38. Stenman UH. Tumor-associated trypsin inhibitor. Clin Chem 2002;48:1206-9.
39. Ohmachi Y, Murata A, Matsuura N, Yasuda T, Monden M, Mori T, et al. Specific expression of the pancreatic-secretory-trypsininhibitor (PSTI) gene in hepatocellular carcinoma. Int J Cancer 1993;55:728-34.
40. Lasson A, Borgström A, Ohlsson K Elevated pancreatic secretory trypsin inhibitor levels during severe inflammatory disease, renal insufficiency, and after various surgical procedures. Scand J Gastroenterol 1986;21:1275-80.
41. Ogawa M. Pancreatic secretory trypsin inhibitor as an acute phase reactant. Clin Biochem 1988;21:19-25.
42. Puolakkainen P, Valtonen V, Paananen A, Schröder T. C-reactive protein (CRP) and serum phospholipase A2 in the assessment of the severity of acute pancreatitis. Gut 1987;28:764-71.
43. Guy O, Bartelt DC, Amic J, Colomb E, Figarella C. Activation peptide of human trypsinogen 2. FEBS Lett 1976;62:150-3.
44. Guy O, Lombardo D, Bartelt DC, Amic J, Figarella C. Two human trypsinogens. Purification, molecular properties, and N-terminal sequences. Biochemistry 1978;17:1669-75.
45. Simpson KW, Beechey-Newman N, Lamb CR, Smyth JB, Hughes G, Coombe K, et al. Cholecystokinin-8 induces edematous pancreatitis in dogs associated with short burst of trypsinogen activation. Dig Dis Sci 1995;40:2152-61.
46. Ohlsson K. Interactions in vitro and in vivo between dog trypsin and dog plasma protease inhibitors. Scand J Clin Lab Invest 1971;28:220-3.